DreamPharm Products:
Lutein-20||Herbs for headache, fever, and migraine ||
Milk thistle||Saw palmetto||
Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract||
Ginseng and Ginkgo||Hair Million||
DHEA||Coenzyme Q10||
Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.||
Weight loss herbal formula for menopause and pms||Ginkgo biloba||
Colon cleansing, Laxative||ViaVita, Lecithin for healthy liver
Fatty acids resources:
Pathogen research abs 1 || Pathogen research abs 2 || Pathogen research abs 3 || Pathogen research abs 4 || Pathogen research abs 5 ||
Hormone and endocrine research abs 1 || Hormone and endocrine research abs 2 || Hormone and endocrine research abs 3 || Hormone and endocrine research abs 4 || Hormone and endocrine research abs 5
comcast.net
More than 60% of patients on chronic haemodialysis (HD) have a serum phosphate level above 5.5 mg/dl (1.75 mmol/l), which recently has been recommended as an appropriate target in patients with end-stage renal disease (ESRD). Preventing hyperphosphataemia and elevated Ca x P product not only ameliorates the progression of secondary hyperparathyroidism and bone disease, but also appears to reduce cardio-vascular morbidity and mortality from vascular calcifications. Dietary phosphate restriction and the administration of aluminium and calcium salts have been the principal means of phosphate control over the last decade. Unfortunately, the protean disturbances of toxic aluminium accumulation in the body virtually eliminated aluminium from clinical practice. Calcium-based therapy, although well tolerated, results in frequent hypercalcaemia when administered concurrently with vitamin D analogues, despite a decrease in the concentration of dialysate calcium. Sevelamer (Renagel((R))) has been a novel, non-absorbable calcium- and aluminium-free synthetic polymer. In initial studies, sevelamer reduced serum phosphate, Ca x P product and parathyroid hormone (PTH) in a manner comparable with calcium acetate therapy. However, the effect on PTH levels may prove to be inconsistent. It seems somewhat less effective in binding phosphate than aluminium, although no direct comparisons have been made. In a recent study, it attenuated the progression of vascular calcification in HD patients. It also binds bile acids, resulting in substantially lower low-density lipo-protein cholesterol levels. The major obstacle to its current use is a substantial increase in the cost associated with sevelamer therapy.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12817070&dopt=Abstract [PubMed - in process]
J Hypertens. 2003 Jul;21(7):1355-62.
Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.
CNR, Institute of Biomedicine, Epidemiology and Pathophysiology of Renal Diseases and Hypertension and Division of Nephrology, Morelli Hospital, Reggio Calabria, Italy. carmine.zoccalin.it
OBJECTIVE: Neuropeptide Y (NPY) is released during sympathetic stimulation and mediates the central effects of the adipostatic hormone leptin. The plasma concentration of NPY and leptin is increased in patients with end stage renal disease (ESRD), but it is unknown whether these substances are related to biochemical markers of sympathetic activity and to alterations in left ventricular (LV) mass and function in these patients. DESIGN: We investigated the relationship between NPY, norepinephrine (NE), leptin and echocardiographic measurements in a cross-sectional study in 198 patients with ESRD. RESULTS: NPY was directly related to plasma NE and heart rate but it was largely independent of arterial pressure and of retention of metabolic waste products. NPY was significantly higher in patients with LV hypertrophy and in those with LV systolic dysfunction than in those without these alterations. Of note, NPY emerged as an independent correlate of LV mass index and of LV ejection fraction (LVEF) (both P <or= 0.002) in multiple linear regression analyses including a series of cardiovascular risk factors. Furthermore in a multiple logistic regression model patients in the top NPY tertile had a risk for LV concentric hypertrophy that was 18.10 (95% confidence interval: 5.87-55.83) times higher than in those in the first tertile (P < 0.001). Leptin was unrelated to NPY as well as to LV mass and to systolic function. CONCLUSIONS: Elevated NPY is independently associated with LV concentric hypertrophy and systolic dysfunction in ESRD. It remains to be seen whether these links contribute to the high cardiovascular mortality in these patients.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12817184&dopt=Abstract [PubMed - in process]
Am J Clin Pathol. 2003 Jun;119(6):801-6.
Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors.
Nasser SM, Faquin WC, Dayal Y.
Department of Pathology, Massachusetts General Hospital, Boston, USA.
The expression of sex hormone receptors in some tumors suggests a role for these receptors in tumor pathogenesis and therapy. Previous studies of the expression of estrogen and progesterone receptors in salivary gland tumors have reported conflicting results. We evaluated the immunohistochemical expression of androgen, estrogen, and progesterone receptors (AR, ER, and PR) in a series of 78 formalin-fixed, paraffin-embedded salivary gland tumors. Immunoreactivity for AR was seen in 14 of 14 carcinoma ex pleomorphic adenomas, 6 of 6 salivary duct carcinomas, and 2 of 2 basal cell adenocarcinomas but in only 2 of 10 acinic cell carcinomas, mucoepidermoid carcinomas, and adenoid cystic carcinomas each. AR expression was distributed evenly between the sexes. ER and PR were expressed in only a few cases of salivary gland tumors. All 26 benign salivary gland tumors were negative for AR, ER, and PR. The uniform expression of AR exclusively in a subset of malignant salivary gland tumors suggests a possible role for AR in the histogenesis and possibly in the clinical management of these malignant salivary gland tumors.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12817426&dopt=Abstract
J Comp Pathol. 1999 Apr;120(3):301-6.
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor).
Yoshikawa K, Matsuura S, Tsuchiya T, Kadota K.
Iida Livestock Hygiene Service Centre, 2-678 Ootemachi, Iida, Nagano, 395-0034, Japan.
A pancreatic endocrine carcinoma with lung metastases was found in a 15-year-old male raccoon. This tumour was characterized by great variation in cell size and production of multiple polypeptide hormones. Endocrine markers expressed by the neoplastic cells were, in descending order of frequency, chromogranin A, pancreatic polypeptide (PP), glucagon, somatostatin and insulin. Co-expression of PP and glucagon, somatostatin or insulin was demonstrated immunohistochemically with consecutive sections, and cells with both glucagon and insulin were also observed. The pattern of co-expression was similar to that in the earliest stages of murine pancreatic development. Amyloid deposits in the islets of Langerhans, which reacted with antibody to islet amyloid polypeptide, were thought to be associated with age. 1999 W.B. Saunders Company Ltd.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10213674&dopt=Abstract
Poult Sci. 2003 Jun;82(6):1042-8.
Photoresponsiveness of turkey breeder hens changes during the egg-laying season: relative and absolute photorefractoriness.
Siopes TD, Proudman JA.
Department of Poultry Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, North Carolina 27695-7608, USA. tom_siopecsu.edu
Photosensitive species undergo neuroendocrine changes during a reproductive season that cause them to gradually become unresponsive to a photoperiod that initially stimulated reproduction. They may first become relatively photorefractory (rPR), when they will cease egg laying only if photoperiod is reduced, and then absolutely photorefractory (aPR), when they will cease laying despite long day length. Our objective was to test the photoresponsiveness of breeder turkey hens during egg production at various times following photostimulation and to relate photoresponsiveness to rPR and aPR as well as plasma levels of prolactin (PRL) and luteinizing hormone (LH). Hens were maintained in cages in light-controlled facilities and photostimulated at 31 wk of age (September) with a photoperiod of 16L:8D. At 8, 14, and 20 wk after photostimulation, treated hens received a 2-wk exposure to an 11.5L:12.5D photoperiod and were then returned to 16L:8D. Exposure to the shortened photoperiod at 8 wk of photostimulation resulted in three distinct responses of declining egg production: nonresponders (NR, 32.7% of hens), partial responders (PAR, 43.9%), or full responders (FR, 23.4%). Egg production returned to control levels following return to a 16L:8D photoperiod. This response repeated at the 14- and 20-wk treatment periods but with greater declines in egg production in the NR and PAR groups. The incidence of subsequent aPR in the NR, PAR, and FR groups was 5.7, 8.5 and 24%, respectively, as compared to 23.3% for the controls. Plasma LH and PRL concentrations also declined in response to 11.5L:12.5D and also rebounded following return to 16L:8D. The hormonal responses of NR, PAR, and FR were similar. We conclude that turkey hens exhibit varying degrees of rPR early during the egg laying season and that the incidence and severity of the rPR response increases as the laying season progresses. Further, PRL and LH levels did not reflect the differences in egg production among the responder and nonresponder groups to changes in photoperiod.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12817463&dopt=Abstract
Natural Herbal Supplement: Hair Million
Hair Loss, or alopecia is a concern
for increasing number of folks in aging society. Loss of hair is a visible problem, and affects the appearance and changes identity of a person.
The phenomenon of hair thinning and hair loss is most commonly associated with natural aging, although there are many other causes of hair loss, which include inherited or genetic conditions, illnesses, malnutrition, stress, hormonal problems, chemotherapy, and use of some drugs.
Hair growth is a sophisticated biological process, which has not yet been completely understood. A multitude of therapeutic measures, including drugs, surgery, and suppelements have been made available, and used. However, due to the heterogeneity in the underlying cause, there is no perfect cure for all hair loss cases. Most of chemical drugs and hair transplantation surgeries are not free from varying degrees of undesirable side effects on health.
Hair Million is an alternative solution to hair loss problems. Anecdotally, it shows prositive results and improvement for age-related hair thinning and hair loss for a fraction of people who take it. We do not know the mechanisms of action as to how Hair Million works to help stop hair loss, and promote hair growth. We only know by anecdotal observations. There has been no clinical trials nor placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth. However, there are two merits in this hair restoration herbal formula:
Firstly, Hair Million is rather inexpensive, and secondly, it is made of well known herbs that are safe when consumed in regular quantities.
DreamPharm Online Healthy Supplements ||
Constipation relief, laxative, colon cleansing ||
Lutein ||
Progesterone Cream ||
Natural herbal formula for hair loss problems ||